{
    "nctId": "NCT00027534",
    "briefTitle": "Vaccine Therapy in Treating Patients With Advanced or Metastatic Cancer",
    "officialTitle": "A Phase I Study Of Active Immunotherapy With Autologous Dendritic Cells Infected With CEA-6D Expressing Fowlpox -Tricom In Patients With Advanced Or Metastatic Malignancies Expressing CEA",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer, Colorectal Cancer, Gallbladder Cancer, Gastric Cancer, Head and Neck Cancer, Liver Cancer, Ovarian Cancer, Pancreatic Cancer, Testicular Germ Cell Tumor",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 14,
    "primaryOutcomeMeasure": "Safety",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Histologically confirmed advanced or metastatic malignancy expressing CEA\n\n  * Metastatic disease meeting one of the following criteria:\n\n    * Measurable or nonmeasurable\n    * History of metastases but no current evidence of disease, meeting one of the following criteria:\n\n      * Unresectable peritoneal or lymph node metastases that cannot be detected by imaging\n      * Treated or resected metastatic disease considered at high risk of recurrence (predicted 5-year disease-free survival of less than 50%)\n\n        * Must have completed treatment that rendered no evidence of disease within the past year\n* CEA-expressing malignancy is defined by any of the following:\n\n  * Immunohistochemical staining (at least 50% of the tumor has at least a moderate intensity of staining)\n  * CEA level in peripheral blood greater than 2.5 \u00b5g/L\n  * Tumor known to be universally CEA positive (e.g., colon and rectal cancer)\n* Received prior therapy with possible survival benefit or refused such therapy\n* Prior resection of brain metastases allowed provided no metastasis by CT scan or MRI of the brain within 1 month of enrollment\n* Hormone receptor status:\n\n  * Not specified\n\nPATIENT CHARACTERISTICS:\n\nAge\n\n* 18 and over Sex\n* Male or female Menopausal status\n* Not specified Performance status\n* Karnofsky 70-100% Life expectancy\n* More than 6 months\n\nHematopoietic\n\n* WBC at least 3,000/mm\\^3\n* Absolute lymphocyte count at least 1,000/mm\\^3\n* Platelet count at least 100,000/mm\\^3\n* Hemoglobin at least 9 g/dL (transfusion or epoetin alfa allowed) Hepatic\n* Bilirubin less than 2.0 mg/dL\n* SGOT/SGPT less than 1.5 times upper limit of normal\n* No active acute or chronic viral hepatitis\n* Hepatitis B surface antigen negative\n* Hepatitis C negative\n* No other hepatic disease that would preclude study entry\n\nRenal\n\n* Creatinine less than 2.5 mg/dL\n* No active acute or chronic urinary tract infection\n\nCardiovascular\n\n* No New York Heart Association class III or IV heart disease Immunologic\n* HIV negative\n* No history of autoimmune disease, including, but not limited to, the following:\n\n  * Inflammatory bowel disease\n  * Systemic lupus erythematosus\n  * Rheumatoid arthritis\n  * Ankylosing spondylitis\n  * Scleroderma\n  * Multiple sclerosis\n* No allergy to eggs or any component of study vaccine Other\n* No active acute or chronic infection\n* No concurrent serious acute or chronic illness that would preclude study entry\n* No other medical or psychological impediment that would preclude study entry\n* No other malignancy within the past 5 years except nonmelanoma skin cancer, controlled carcinoma in situ of the cervix, or controlled superficial bladder cancer\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective contraception\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy\n\n* At least 4 weeks since prior biologic therapy and recovered\n* No other concurrent immunotherapy\n\nChemotherapy\n\n* At least 4 weeks since prior chemotherapy and recovered\n* No concurrent chemotherapy\n\nEndocrine therapy\n\n* At least 4 weeks since prior hormonal therapy and recovered\n* At least 6 weeks since prior steroids except steroids used as premedication for chemotherapy or for contrast-enhanced studies\n* No concurrent steroids\n\nRadiotherapy\n\n* Prior palliative radiotherapy (including systemic radiolabeled compounds) for unstable or painful bone metastases in weight-bearing bones may be allowed\n* At least 4 weeks since prior radiotherapy and recovered\n* No concurrent radiotherapy\n\nSurgery\n\n* Not specified\n\nOther\n\n* At least 4 weeks since any other prior therapy (including experimental therapy) and recovered\n* No concurrent immunosuppressives (e.g., azathioprine or cyclosporine)",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}